Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Ta ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie ... Kim is set to become one of only a handful of women CEOs leading Big Pharma companies, joining ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and representative director, effective from June 2026. The decision was unanimously ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...

CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process “The Board of ...

Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor ...

Takeda Pharmaceutical 4502-1.26%decrease; red down pointing triangle named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but ...

We apologize, but this video has failed to load. “The Board of Directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company’s success under Christophe Weber ...